Teva Buys Allergan’s Generic Drug For $40.5 Billion

Photo By clarita of Morguefile.com

Photo By clarita of Morguefile.com

Israel’s Teva Pharmaceutical Industries announced the purchase of the Dublin-based Allergan’s generic pharmaceuticals business for $40.5 billion today.

Consequently, Teva will not be dealing with the pharmaceutical company Mylan anymore. Allergan is set to receive $33.75 billion in cash, since Teva has been valued at $6.75 billion in shares.

Erez Vigodman, the president and CEO of Teva, said the following in a statement, “Through our acquisition of Allergan Generics, we will establish a strong foundation for long-term, sustainable growth, anchored by leading generics capabilities and a world-class late-stage pipeline that will accelerate our ability to build an exceptional portfolio of products – both in generics and specialty as well as the intersection of the two.”

Teva aims to save money and become more efficient by combining with a big and generic drug company like Allergan.

Generic drugs are less expensive than name-brand drugs, but some generics have been too expensive due to a lack of competition by the manufacturers. Therefore, by combining the two drug companies, Teva believes that everybody, including consumers, will benefit from this transaction.

This entry was posted in Health and tagged , , , , , . Bookmark the permalink.
You are not authorized to see this part
Please, insert a valid App IDotherwise your plugin won't work.

Leave a Reply

Your email address will not be published. Required fields are marked *